Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human immunodeficiency virus 1

ABSTRACT: HIV-1 Envelope Clinical Isolates from Vicriviroc Resistant Subjects

PROVIDER: PRJNA317236 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3469710.fastq.gz	Fastqsanger.gz
	SRR3469710_1.fastq.gz	Fastqsanger.gz
	SRR3469710_2.fastq.gz	Fastqsanger.gz
	SRR3469711.fastq.gz	Fastqsanger.gz
	SRR3469711_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Human immunodeficiency virus 1

Project description:Full-length HIV-1 envelope sequences

| PRJNA320111 | ENA

Human immunodeficiency virus 1

Project description:Deep Sequencing of Protease Inhibitor Resistant HIV Patient Isolates Reveals Patterns of Correlated Mutations in Gag and Protease

| PRJNA759627 | ENA

Human immunodeficiency virus 1

Project description:HIV-1 promoter single nucleotide polymorphisms are associated with clinical disease severity

| PRJNA309974 | ENA

Innate protection against intrarectal SIV acquisition by a live Simian-Human immunodeficiency virus vaccine

Project description:Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical against SIV/HIV acquisition. Here, we evaluated the efficacy of a SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded as there was no cross-reactivity between SIV and SHIV Envelope antibodies. After eight low-dose rectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated 83% efficacy, compared to six naïve controls, suggesting protection could be achieved in the absence of anti-Envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for the preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation, and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 (PF4) on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity and may provide new opportunities for novel HIV vaccines or therapeutic strategy development.

2024-09-30 | GSE242726 | GEO

Human immunodeficiency virus

Project description:Comparison of HIV-1 and HIV-2 Mutagenesis by Illumina Sequencing

| PRJNA287455 | ENA

Human immunodeficiency virus 1

Project description:Guiding the humoral response against HIV-1 toward a MPER proximal region by immunization with a VLP-formulated antibody-selected envelope variant

| PRJNA495005 | ENA

Human immunodeficiency virus 1

Project description:Broad neutralizing HIV antibodies

| PRJNA294363 | ENA

Human immunodeficiency virus 1

Project description:HIV LTR terminus sequence

| PRJDB9357 | ENA

Human immunodeficiency virus 1

Project description:HIV-1 quasispecies analysis

| PRJDB3502 | ENA

Human immunodeficiency virus 1

Project description:Polymorphisms of HIV-1 integrase